Healthcare Industry News: Transdermal
News Release - January 9, 2007
Agile Therapeutics Expands Senior Management TeamCompany Continues Development of Low-Dose Contraceptive Patch
PRINCETON, N.J., Jan. 9 (HSMN NewsFeed) -- Agile Therapeutics, Inc., an early-stage company focused on the development of a low estrogen dose, seven- day Transdermal contraceptive patch, has made several key additions to its management team.
Dr. Gary Shangold, M.D., FACOG, an OB/GYN and Reproductive Endocrinologist, has been engaged by the company as a Senior Scientific Advisor. Dr. Shangold has extensive experience in contraceptive clinical development and regulatory affairs as well as small-company management experience. He recently served as the CEO of NovaDel Pharma and had prior experience at Johnson & Johnson, where he played a pivotal role in the development of Ortho Evra, the first and only contraceptive patch on the market today.
Mr. Greg Arnold, I.E., has joined the company as Vice President of Manufacturing and Scale Up. In this role, Mr. Arnold, a recognized expert in the industry, is bringing his extensive knowledge of Transdermal manufacturing and technology to bear on the development and validation of a commercial-scale manufacturing process for Agile's low-dose contraceptive patch. He has held related positions at a number of companies, including Vyteris, Theratech, and Cygnus.
Mr. Bob Conway, M.E., has joined the team as Vice President of Operations. He is performing a key role in executing the company's business model, which requires careful coordination of an extensive network of laboratory and service providers. Mr. Conway has broad medical product development experience and, in addition to managing an independent engineering and project management consulting firm, has also worked for Johnson & Johnson on the development and manufacturing of medical devices.
"We've been able to assemble a very high performing team to manage the progress of our lead product in the development process," said Thomas M. Rossi, Ph.D., CEO and President of Agile Therapeutics. "These key additions will help us achieve our vision of bringing value to women who want an easy- to-use contraceptive with the advantages of a low estrogen dosing profile."
Agile Therapeutics' contraceptive patch is currently in phase 2 clinical development. The company is privately held and supported by high-quality health care investors, including ProQuest, a healthcare venture capital firm that is managing over $875 million; the Hillman Company and its Affiliates, a diversified investment firm active in venture capital investing for over 25 years; TL Ventures, with over $1.4 billion under management; and PA Early Stage Partners, with more than $235 million under management.
About Agile Therapeutics
Agile Therapeutics, Inc. is a pharmaceutical product development company founded in 1997 based on developing novel pharmaceutical products utilizing its proprietary Transdermal drug delivery technology. For more information, log on to http://www.agiletherapeutics.com.
Source: Agile Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.